LYSMD2
LysM and putative peptidoglycan-binding domain-containing protein 2
Also known as: LYSM2_HUMAN, MGC35274
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8IV50
- Gene
- LYSMD2
- Ensembl
- ENSG00000140280
- Chromosome
- 15
- Canonical length
- 215 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nuclear bodies,Mitochondria
OverviewNCBI Gene
No narrative summary is available for LYSMD2 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
215 residues, UniProt reviewed canonical sequence.
>Q8IV50|LYSMD2
1 MADSSPALSL REGGPRAPRP SAPSPPPRSR SGSESEEAEL SLSLARTKTR SYGSTASVRA
61 PLGAGVIERH VEHRVRAGDT LQGIALKYGV TMEQIKRANK LFTNDCIFLK KTLNIPVISE
121 KPLLFNGLNS IDSPENETAD NSFSQEEEPV VAGEDLPPPS PQESDVQPVQ PEEVSARDFL
181 QRLDLQIKLS TQAAKKLKEE SRDEESPYAT SLYHSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LYSMD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.57
- Highest tissue expression
- 44 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 44 nTPM
- cerebellum: 37 nTPM
- hypothalamus: 35 nTPM
- basal ganglia: 34 nTPM
- hippocampal formation: 31 nTPM
- amygdala: 31 nTPM
Single-cell type
- early spermatids: 174 nCPM
- late spermatids: 134 nCPM
- pdcs: 98 nCPM
- neuroendocrine cells: 80 nCPM
- late primary spermatocytes: 76 nCPM
- kupffer cells: 63 nCPM
Immune cell
- neutrophil: 113 nTPM
- eosinophil: 77 nTPM
- non-classical monocyte: 62 nTPM
- plasmacytoid DC: 55 nTPM
- naive B-cell: 50 nTPM
- intermediate monocyte: 49 nTPM
Brain region
- hypothalamus: 50 nTPM
- pons: 50 nTPM
- cerebral cortex: 47 nTPM
- thalamus: 40 nTPM
- medulla oblongata: 37 nTPM
- basal ganglia: 37 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.91
- gnomAD pLI
- 0.42
- gnomAD missense Z
- 0.21
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LYSMD2 as an antibody target. Whether an autoantibody or antibody against LYSMD2 could matter depends on whether native LYSMD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LYSMD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LYSMD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...